- Home
- CORT vs ROIV Comparison
CORT vs ROIV Comparison
Compare CORT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CORT | ROIV |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CORT | ROIV |
|---|---|---|
| Price | $88.01 | $22.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $139.00 | $21.94 |
| AVG Volume (30 Days) | 690.9K | ★ 6.7M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $741,172,000.00 | $20,329,000.00 |
| Revenue This Year | $23.79 | N/A |
| Revenue Next Year | $40.97 | $376.94 |
| P/E Ratio | $100.74 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $49.00 | $8.73 |
| 52 Week High | $117.33 | $22.45 |
Technical Indicators
Market Signals| Indicator | CORT | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 68.54 | 68.21 |
| Support Level | $81.31 | $20.14 |
| Resistance Level | $87.19 | $21.48 |
| Average True Range (ATR) | 2.86 | 0.66 |
| MACD | 0.74 | -0.02 |
| Stochastic Oscillator | 93.81 | 87.12 |
Price Performance
Historical ComparisonAbout CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.